According to a recent study, the choice of anaesthesia may change the metastatic process of breast cancer by affecting the cytokine and microenvironment.
The study was led by Stony Brook University Cancer Center researchers. It was published in the journal Nature Communications.
Jun Lin, MD, Ph.D., of the Department of Anesthesiology in the Renaissance School of Medicine at Stony Brook University, and colleagues found that a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl - sevoflurane anesthesia leads to more metastatic burden in the lung, after breast tumour resecting surgery than propofol in laboratory models.
The study findings may serve as a guide to design clinical trials for clinicians to optimise anaesthesia choice for breast cancer surgery in order to achieve the best long-term outcomes.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.